[go: up one dir, main page]

NO20073244L - Konjugeringsprodukt - Google Patents

Konjugeringsprodukt

Info

Publication number
NO20073244L
NO20073244L NO20073244A NO20073244A NO20073244L NO 20073244 L NO20073244 L NO 20073244L NO 20073244 A NO20073244 A NO 20073244A NO 20073244 A NO20073244 A NO 20073244A NO 20073244 L NO20073244 L NO 20073244L
Authority
NO
Norway
Prior art keywords
peptide
integrin
selectively inhibits
konjugeringsprodukt
ngr motif
Prior art date
Application number
NO20073244A
Other languages
English (en)
Inventor
Angelo Corti
Flavio Curnis
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of NO20073244L publication Critical patent/NO20073244L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et peptid som selektivt inhiberer a,P3-integrin som omfatter deamideringsproduktet av et peptid omfattende NGR-motivet. ?Et peptid som selektivt inhiberer a,P3-integrin som omfatter deamideringsproduktet av et peptid omfattende NGR-motivet. Et peptid som selektivt inhiberer ?v?3-integrin som omfatter deamideringsproduktet av et peptid omfattende NGR-motivet.
NO20073244A 2004-12-23 2007-06-22 Konjugeringsprodukt NO20073244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63815804P 2004-12-23 2004-12-23
PCT/IB2005/004058 WO2006067633A2 (en) 2004-12-23 2005-12-21 Conjugation product

Publications (1)

Publication Number Publication Date
NO20073244L true NO20073244L (no) 2007-09-20

Family

ID=36602131

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073244A NO20073244L (no) 2004-12-23 2007-06-22 Konjugeringsprodukt

Country Status (12)

Country Link
US (2) US7795386B2 (no)
EP (2) EP1831254B1 (no)
JP (1) JP2008525424A (no)
KR (1) KR20070102684A (no)
CN (1) CN101124243A (no)
AU (1) AU2005317684B2 (no)
CA (1) CA2593964A1 (no)
EA (1) EA013967B1 (no)
ES (1) ES2388068T3 (no)
IL (2) IL183710A (no)
NO (1) NO20073244L (no)
WO (1) WO2006067633A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124726A2 (en) * 2005-05-12 2006-11-23 The General Hospital Corporation Novel biotinylated compositions
GB0624308D0 (en) * 2006-12-05 2007-01-17 Molmed Spa Combination product
GB0708864D0 (en) * 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
SI3281952T1 (sl) 2007-10-30 2020-09-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
RS52460B (sr) * 2008-05-13 2013-02-28 Molmed Spa Konjugati za lečenje mezotelioma
WO2010005693A1 (en) * 2008-06-23 2010-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclized ngr peptide compounds, compositions, and methods of their use
WO2010056378A2 (en) 2008-11-14 2010-05-20 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
TWI494566B (zh) * 2009-09-24 2015-08-01 加州大學董事會 膀胱癌特異性配體肽
US9580485B2 (en) * 2011-07-27 2017-02-28 Philogen S.P.A. IL-12 immunoconjugate
GB201204868D0 (en) * 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US9526800B2 (en) * 2012-03-28 2016-12-27 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
US10024860B2 (en) 2012-03-28 2018-07-17 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
US9234007B2 (en) 2012-07-02 2016-01-12 University Of South Florida RGD mimetic γ-AApeptides and methods of use
WO2014036427A1 (en) 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
ES2743423T3 (es) 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
US9645155B2 (en) 2013-08-28 2017-05-09 University Of South Florida Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβ40 aggregates
FR3010527A1 (fr) * 2013-09-11 2015-03-13 Univ Claude Bernard Lyon Procede de caracterisation de particules
CN103483422B (zh) * 2013-09-22 2015-06-17 中国人民解放军第四军医大学 一种ngr多肽放射性药物及其制备方法与应用
WO2015074792A1 (en) 2013-11-25 2015-05-28 Ontochem Gmbh Method for diagnosing g-protein coupled receptor-related diseases
CR20180087A (es) 2015-07-16 2018-05-14 Philogen Spa Inmunoconjugados de il22
CN108699164B (zh) * 2016-03-02 2022-06-07 法玛科技顾问股份有限公司 双重标靶药物载体
JP7608336B2 (ja) * 2018-11-30 2025-01-06 フォンダッツィオーネ・セントロ・サン・ラッファエーレ 中枢神経系原発リンパ腫の併用治療

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
WO1984002129A1 (fr) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6068829A (en) * 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
EP0773441B1 (en) 1995-09-11 2000-08-02 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo and methods of identifying same
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
AU4982200A (en) 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
WO2001051629A2 (en) * 2000-01-13 2001-07-19 Panorama Research, Inc. Circularly permutated, interaction-activated proteins
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
WO2002047537A2 (en) 2000-12-11 2002-06-20 Regents Of The University Of Michigan Compositions and methods for in situ and in vivo imaging of cells and tissues
JP4029041B2 (ja) 2001-01-10 2008-01-09 アメリカ合衆国 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate

Also Published As

Publication number Publication date
EA200701053A1 (ru) 2008-06-30
IL202570A0 (en) 2011-08-01
EP1831254B1 (en) 2012-06-06
EP1831254A2 (en) 2007-09-12
AU2005317684A1 (en) 2006-06-29
CA2593964A1 (en) 2006-06-29
IL183710A0 (en) 2008-04-13
ES2388068T3 (es) 2012-10-08
EA013967B1 (ru) 2010-08-30
HK1106781A1 (en) 2008-03-20
WO2006067633A3 (en) 2007-04-05
US7795386B2 (en) 2010-09-14
US20090068106A1 (en) 2009-03-12
CN101124243A (zh) 2008-02-13
JP2008525424A (ja) 2008-07-17
US20110076234A1 (en) 2011-03-31
WO2006067633A2 (en) 2006-06-29
KR20070102684A (ko) 2007-10-19
IL183710A (en) 2012-01-31
AU2005317684B2 (en) 2012-02-16
EP2364995A1 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
NO20073244L (no) Konjugeringsprodukt
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
EA200701790A1 (ru) Твёрдый фармацевтический дозированный состав
CA120928S (en) Sprayer
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CA119296S (en) Bottle
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DK1869019T3 (da) Bicycliske [3.1.0]heteroarylamider som glycintransportinhibitorer type I
ATE536109T1 (de) Kleidungsstück mit verbesserter kniestütze
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
USD529537S1 (en) Type font
ATE330017T1 (de) Kallikrein gen
ECSP088555A (es) Composiciones farmacéuticas
CA120393S (en) Track for display shelving
CA115742S (en) Sprayer tank
CA114146S (en) Correction and glue tape dispenser
CA118307S (en) Pasta dispenser disk
UY28344A1 (es) Nuevos compuestos
CA116012S (en) Product dispenser
CA119778S (en) Package
USD527411S1 (en) Type font
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
CA102731S (en) Fragrance dispenser
TW200724152A (en) Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application